Circulating Tumor Cell-based Molecular Responses Stratify EGFR-TKI Efficacy in Patients with <i>EGFR</i>-Mutant Lung Cancer

CTC analysis using CCM-CTCD shows potential as a biomarker for predicting treatment response and prognosis in EGFR-mutant NSCLC. Stratification by CTC molecular response may inform risk-adapted treatment; however, its clinical utility remains to be established. Prospective studies are warranted to validate these findings and determine the role of CTC-guided decision-making.

Authors

Institutions

Publication Details

Journal
Cancer Research and Treatment
Published
2026-01-27
DOI
https://doi.org/10.4143/crt.2025.672
Primary Topic
Lung Cancer Treatments and Mutations
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Circulating Tumor Cell-based Molecular Responses Stratify EGFR-TKI Efficacy in Patients with EGFR-Mutant Lung Cancer

Wonrak Son, Mina Han, Min Hee Hong, Hyun Bang Shin et al.
Cancer Research and Treatment
Lung Cancer Treatments and Mutations
article

Circulating Tumor Cell-based Molecular Responses Stratify EGFR-TKI Efficacy in Patients with EGFR-Mutant Lung Cancer

Wonrak Son, Mina Han, Min Hee Hong, Hyun Bang Shin, Gamin Kim, Hye Ryun Kim, Chang Gon Kim, Chaeyeon Kim, Jungmin Lee, Seoyoung Lee, Minseok S Kim, Hyeong Jung Woo
article en

Abstract

CTC analysis using CCM-CTCD shows potential as a biomarker for predicting treatment response and prognosis in EGFR-mutant NSCLC. Stratification by CTC molecular response may inform risk-adapted treatment; however, its clinical utility remains to be established. Prospective studies are warranted to validate these findings and determine the role of CTC-guided decision-making.

Cancer Research and Treatment
Daegu Gyeongbuk Institute of Science and Technology (KR), Yonsei University (KR), NovaCell Technology (South Korea) (KR), Gangnam Severance Hospital (KR)
National Research Foundation, Yonsei University, Korea Health Industry Development Institute, Ministry of Science and ICT, South Korea
Peace, Justice and strong institutions
Openalex Percentile: Top 78%
Lung Cancer Treatments and Mutations
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Circulating Tumor Cell-based Molecular Responses Stratify EGFR-TKI Efficacy in Patients with <i>EGFR</i>-Mutant Lung Cancer — Wonrak Son, Mina Han, et al. · Cancer Research and Treatment (2026) | TGRS Research Map | TGRS